{"id":48891,"date":"2022-09-27T23:01:56","date_gmt":"2022-09-27T21:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/"},"modified":"2022-09-27T23:01:56","modified_gmt":"2022-09-27T21:01:56","slug":"thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/","title":{"rendered":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers"},"content":{"rendered":"
\n

\nApproval also marks the second NGS-based companion diagnostic to identify RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/i>\n<\/p>\n

CARLSBAD, Calif.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific\u2019s Oncomine Dx Target Test<\/a> as a companion diagnostic (CDx) to aid in selection of patients with RET<\/i>-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET<\/i>-fusion positive advanced or metastatic thyroid cancer and RET<\/i>-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly\u2019s Retevmo (selpercatinib). This marks the Oncomine Dx Target Test\u2019s first approval as a CDx for a therapy targeting RET<\/i>-positive thyroid cancer and second approval associated with RET<\/i>-positive NSCLC.\n<\/p>\n

<\/a><\/p>\n

\nInitially approved in 2020, Retevmo is a selective RET<\/i> kinase inhibitor and was the first therapy approved for patients with advanced RET<\/i>-driven lung and thyroid cancers. RET<\/i> (rearranged during transfection) alterations are found in approximately 2% of patients with NSCLC, which is the leading cause of adult cancer death in the United Statesi<\/sup>, 60% of patients with MTC and 20% in other thyroid cancers.ii<\/sup>\n<\/p>\n

\nThe Oncomine Dx Target test is a next-generation sequencing (NGS)-based test that can detect multiple alterations at once from a small sample size, helping to quickly match patients with the appropriate targeted therapy. It is also approved in Japan as a companion diagnostic for Retevmo in the same indications. The test is the only globally distributable NGS CDx solution that has received regulatory approval in 17 countries for 15 targeted therapies, covering more than 550 million lives globally.\n<\/p>\n

\nGarret Hampton, president, clinical next generation sequencing and oncology at Thermo Fisher Scientific in his statement regarding the approval said, \u201cFollowing the Oncomine Dx Target Test\u2019s first approval in 2017, we have worked to advance access to companion diagnostics for targeted therapies on a global scale.\u201d He also added, \u201cAs we continue to pursue additional approvals alongside our biopharma partners, we remain committed to broadening access to NGS-based testing to ensure patients and clinicians everywhere can benefit from it.\u201d\n<\/p>\n

\nAbout Thermo Fisher Scientific<\/b>\n<\/p>\n

\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com<\/a>.\n<\/p>\n

\ni<\/sup> https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html<\/a>
ii<\/sup> https:\/\/www.cell.com\/trends\/cancer\/fulltext\/S2405-8033(21)00148-5<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact Information:
\n
Mauricio Minotta
\n
Phone: 760-805-5266
\n
E-mail: Mauricio.Minotta@thermofisher.com<\/a><\/p>\n

Jessika Parry
\n
Phone: 419-266-4016
\n
Email: jparry@greenough.biz<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Approval also marks the second NGS-based companion diagnostic to identify RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC) CARLSBAD, Calif.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific\u2019s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48891","6":"format-standard","7":"category-industry"},"yoast_head":"\nThermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Approval also marks the second NGS-based companion diagnostic to identify RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC) CARLSBAD, Calif.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific\u2019s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T21:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\\\/Fusions in Thyroid Cancers\",\"datePublished\":\"2022-09-27T21:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/\"},\"wordCount\":528,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005298\\\/en\\\/1387941\\\/21\\\/Thermo_Fisher_Scientific.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/\",\"name\":\"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\\\/Fusions in Thyroid Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005298\\\/en\\\/1387941\\\/21\\\/Thermo_Fisher_Scientific.jpg\",\"datePublished\":\"2022-09-27T21:01:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005298\\\/en\\\/1387941\\\/21\\\/Thermo_Fisher_Scientific.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005298\\\/en\\\/1387941\\\/21\\\/Thermo_Fisher_Scientific.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\\\/Fusions in Thyroid Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/","og_locale":"en_US","og_type":"article","og_title":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers - Pharma Trend","og_description":"Approval also marks the second NGS-based companion diagnostic to identify RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC) CARLSBAD, Calif.–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific\u2019s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-27T21:01:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers","datePublished":"2022-09-27T21:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/"},"wordCount":528,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/","url":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/","name":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg","datePublished":"2022-09-27T21:01:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220927005298\/en\/1387941\/21\/Thermo_Fisher_Scientific.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-fusions-in-thyroid-ca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations\/Fusions in Thyroid Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48891"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48891\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}